UCERIS with MMX® technology: The power of locally acting budesonide
UCERIS is a locally acting corticosteroid that treats patients with active, mild to moderate ulcerative colitis (UC).
MMX® technology is designed to target delivery of budesonide throughout the full length of the colon.1View Pharmacoscintigraphic Image
UCERIS uses MMX® technology, which is designed to target delivery of budesonide throughout the full length of the colon.1 Targeted delivery is possible because the tablet is coated with a gastro-resistant film that does not dissolve until it reaches pH ≥7.
After reaching the colon, the pill matrix expands, forms a hydrogel, and provides extended release of budesonide in a time-dependent manner. Budesonide has been detected by scintigraphic imaging in the ascending colon between 4 and >24 hours after dosing. The medication is then absorbed into the body and subject to a high first-pass metabolism (80-90%), thereby minimizing side effects.
Unlike other UC therapies, UCERIS is a single pill taken once a day by mouth for up to 8 weeks.
When transferring patients from glucocorticosteroid treatment with higher systemic effects to glucocorticosteroids with lower systemic effects, such as UCERIS, taper patients slowly to avoid withdrawal effects.
UCERIS is designed for targeted local action at the entire site of UC1
UCERIS is designed for targeted local action at the entire site of UC.
KOL Audio: MMX® Technology
Russell D. Cohen, MD
Professor of Medicine, Pritzker School of Medicine
Co-Director, Inflammatory Bowel Disease Center
The University of Chicago Medical Center